Free Trial
NASDAQ:CBIO

Crescent Biopharma (CBIO) Stock Price, News & Analysis

Crescent Biopharma logo
$14.47 -0.23 (-1.56%)
As of 04:00 PM Eastern

About Crescent Biopharma Stock (NASDAQ:CBIO)

Key Stats

Today's Range
$14.27
$16.00
50-Day Range
$11.00
$18.00
52-Week Range
$10.83
$63.00
Volume
122,499 shs
Average Volume
45,642 shs
Market Capitalization
$282.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.60
Consensus Rating
Buy

Company Overview

Crescent Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

CBIO MarketRank™: 

Crescent Biopharma scored higher than 76% of companies evaluated by MarketBeat, and ranked 244th out of 929 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Crescent Biopharma has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Crescent Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Crescent Biopharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Crescent Biopharma are expected to grow in the coming year, from ($0.16) to ($0.03) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Crescent Biopharma is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Crescent Biopharma is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Crescent Biopharma has a P/B Ratio of 1.81. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Short Interest

    There is no current short interest data available for CBIO.
  • Dividend Yield

    Crescent Biopharma does not currently pay a dividend.

  • Dividend Growth

    Crescent Biopharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for CBIO.
  • News Sentiment

    Crescent Biopharma has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Crescent Biopharma this week, compared to 0 articles on an average week.
  • MarketBeat Follows

    1 people have added Crescent Biopharma to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Crescent Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of Crescent Biopharma is held by insiders.

  • Percentage Held by Institutions

    75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Crescent Biopharma's insider trading history.
Receive CBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Crescent Biopharma and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CBIO Stock News Headlines

Crescent Biopharma initiated with a Buy at Jefferies
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
Crescent Biopharma: Chasing The Summit Hype
Crescent Biopharma: Q2 Earnings Snapshot
See More Headlines

CBIO Stock Analysis - Frequently Asked Questions

Crescent Biopharma's stock was trading at $15.7950 at the start of the year. Since then, CBIO shares have decreased by 5.4% and is now trading at $14.94.

Crescent Biopharma, Inc. (NASDAQ:CBIO) issued its quarterly earnings data on Thursday, August, 17th. The biopharmaceutical company reported ($7.00) earnings per share for the quarter, meeting the consensus estimate of ($7.00).

Shares of Crescent Biopharma reverse split before market open on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

Crescent Biopharma's top institutional investors include BVF Inc. IL (7.10%), Commodore Capital LP (2.32%), Perceptive Advisors LLC (2.32%) and Frazier Life Sciences Management L.P. (2.32%).
View institutional ownership trends
.

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

Last Earnings
8/17/2023
Today
8/26/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CBIO
Previous Symbol
NASDAQ:CBIO
CIK
1253689
Employees
50
Year Founded
2003

Price Target and Rating

High Price Target
$28.00
Low Price Target
$22.00
Potential Upside/Downside
+71.4%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
($34.93)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$37.88 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-106.06%
Return on Assets
-86.60%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.21
Quick Ratio
9.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.24 per share
Price / Book
1.81

Miscellaneous

Outstanding Shares
19,550,000
Free Float
17,849,000
Market Cap
$292.08 million
Optionable
No Data
Beta
1.51

Social Links

Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:CBIO) was last updated on 8/26/2025 by MarketBeat.com Staff
From Our Partners